Addition of long acting   agonist is not supported by clinical trial evidence

BMJ ◽  
2012 ◽  
Vol 345 (dec20 10) ◽  
pp. e8361-e8361
Author(s):  
J. R. Manderville
Keyword(s):  
Clinical Trial ◽  
Clinical Trial Evidence ◽  
Long Acting ◽  
Trial Evidence ◽  
Acting Agonist

scholarly journals Sulfonylureas at the Glomerular Battlefield

2018 ◽  
Vol 14 (2) ◽  
pp. 15
Author(s):  
Sanjay Kalra ◽  
Deepak Khandelwal ◽  
Sarita Bajaj ◽  
Ashok Kumar Das
Keyword(s):  
Clinical Trial ◽  
Glucose Homeostasis ◽  
Diabetes Complications ◽  
Cardiovascular Health ◽  
Glucose Lowering ◽  
Meeting Point ◽  
Normal Glucose ◽  
Clinical Trial Evidence ◽  
Trial Evidence

The kidney is important in the context of diabetes not only because it is involved in normal glucose homeostasis, but also because it is one of the most important end organs to be involved in diabetes complications. Glomeruli are the meeting point of both microvascular, or renal; and macrovascular, or cardiovascular, health in diabetes. Sulfonylureas are effective glucose-lowering drugs. While a sulfonylurea-based glucose-lowering strategy is nephro-safe and nephro-protective, this aspect of sulfonylurea pharmaco-biology has not been highlighted earlier. In this editorial, we discuss current preclinical and clinical trial evidence regarding the performance of modern sulfonylureas at the glomerular battlefield.

scholarly journals Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016

2020 ◽  
Vol 3 (11) ◽  
pp. e2024406
Author(s):  
Aviv Ladanie ◽  
Andreas M. Schmitt ◽  
Benjamin Speich ◽  
Florian Naudet ◽  
Arnav Agarwal ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Drug Administration ◽  
Food And Drug Administration ◽  
Cancer Therapies ◽  
Clinical Trial Evidence ◽  
Trial Evidence
Sign in / Sign up

Export Citation Format

Share Document